Prospective Exploratory Cohort Study on Ganglion Cell Degeneration in Retinitis Pigmentosa Patients
NCT ID: NCT07056738
Last Updated: 2025-07-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
130 participants
OBSERVATIONAL
2025-03-01
2030-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
In Depth Observational Clinical Trial Of Retinitis Pigmentosa Patients
NCT05849987
Biomarkers in Retinitis Pigmentosa
NCT06306690
Self-testing Diagnosis Imaging Model for Diabetic Retinopathy
NCT05223556
Long-term Safety of UC-MSC Transplantation in Patients With Retinitis Pigmentosa
NCT05786287
Sparing of the Fovea in Geographic Atrophy Progression
NCT02332343
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
imaging
OCT, OCTA, RNFL-OCT, fundus autofluorescence, fundus imaging, flaremeter, fundus and slit lamp examination
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* minimum age of 18 years (legal adult age in Germany)
* patient consent for study participation
Exclusion Criteria
* reduced cooperation during imaging or examination
* age under 18 years
* presence of additional retinal diseases
* insufficient imaging quality due to hazy media (cornea, lense)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Center Goettingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Emilie Macé
Professor Dr. Emilie Macé, Department of Ophthalmology, Center of Biostructural Imaging
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emilie Macé, Professor
Role: PRINCIPAL_INVESTIGATOR
Else Kroener Fresenius Center for Optogenetic Therapies, University Medical Center Goettingen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
EKFZ Else Kroener Fresenius Center for Optogenetic Therapies, University Medical Center Goettingen
Göttingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-03803
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.